New and emerging therapeutic agents for the treatment of fibromyalgia: an update.

J Pain Res · 2010 · PMC3004640 · PMID 21197313

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

a trend toward significanceP = 0.056so close (0.05 < p ≤ 0.1)

While the results from the 100 mg/day dose group showed a trend toward significance ( P = 0.056), the number of patients in this group was likely too small to produce robust results. 52 Clinical trials have demonstrated the efficacy of milnacipran for both the short- and long-term treatment of FM.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.